BR112012023974A2 - composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto. - Google Patents
composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto.Info
- Publication number
- BR112012023974A2 BR112012023974A2 BR112012023974A BR112012023974A BR112012023974A2 BR 112012023974 A2 BR112012023974 A2 BR 112012023974A2 BR 112012023974 A BR112012023974 A BR 112012023974A BR 112012023974 A BR112012023974 A BR 112012023974A BR 112012023974 A2 BR112012023974 A2 BR 112012023974A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- faah
- treating
- disease
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 101150042613 FA2H gene Proteins 0.000 title abstract 4
- 101150008770 FAAH gene Proteins 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000013465 muscle pain Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 239000001993 wax Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32199210P | 2010-04-08 | 2010-04-08 | |
| PCT/US2011/031040 WO2011126960A1 (en) | 2010-04-08 | 2011-04-04 | Oxazole derivatives useful as modulators of faah |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012023974A2 true BR112012023974A2 (pt) | 2017-09-26 |
Family
ID=44763231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012023974A BR112012023974A2 (pt) | 2010-04-08 | 2011-04-04 | composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9193697B2 (enExample) |
| EP (1) | EP2555772B1 (enExample) |
| JP (1) | JP2013523814A (enExample) |
| CN (1) | CN102917704A (enExample) |
| AU (1) | AU2011238487B2 (enExample) |
| BR (1) | BR112012023974A2 (enExample) |
| CA (1) | CA2793900A1 (enExample) |
| WO (1) | WO2011126960A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5698666B2 (ja) * | 2008-08-04 | 2015-04-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆａａｈの阻害剤として有用なオキサゾール誘導体 |
| US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| EP3580218A1 (en) | 2017-02-08 | 2019-12-18 | Bayer CropScience Aktiengesellschaft | Novel triazole derivatives |
| JP2020506950A (ja) | 2017-02-08 | 2020-03-05 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | トリアゾールチオン誘導体 |
| WO2018145932A1 (en) | 2017-02-08 | 2018-08-16 | Bayer Cropscience Aktiengesellschaft | Triazole derivatives and their use as fungicides |
| JP2020507579A (ja) | 2017-02-10 | 2020-03-12 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | １−（フェノキシ−ピリジニル）−２−（１，２，４−トリアゾール−１−イル）−エタノール誘導体を含む有害微生物を制御するための組成物 |
| JP7252908B2 (ja) * | 2017-06-14 | 2023-04-05 | トレベナ・インコーポレイテッド | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
| WO2020020816A1 (en) | 2018-07-26 | 2020-01-30 | Bayer Aktiengesellschaft | Novel triazole derivatives |
| CN110804048A (zh) * | 2019-11-08 | 2020-02-18 | 暨南大学 | 恶唑酮类化合物及其应用、faah的正电子药物 |
| WO2021101854A1 (en) | 2019-11-19 | 2021-05-27 | Trevena, Inc. | Compounds and methods of preparing compounds s1p1 modulators |
| KR20250033421A (ko) * | 2023-08-29 | 2025-03-10 | 인천대학교 산학협력단 | 옥사졸 유사체를 유효성분으로 포함하는 항노화 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009538358A (ja) * | 2006-05-26 | 2009-11-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター |
| FR2921063B1 (fr) | 2007-09-13 | 2009-12-11 | Sod Conseils Rech Applic | Ligands des recepteurs cannabinoides |
| CA2727245A1 (en) * | 2008-06-11 | 2009-12-17 | Merck Sharp & Dohme Corp. | Imidazole derivatives useful as inhibitors of faah |
| JP5698666B2 (ja) * | 2008-08-04 | 2015-04-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｆａａｈの阻害剤として有用なオキサゾール誘導体 |
| AU2011209754A1 (en) * | 2010-01-28 | 2012-07-26 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions for the treatment of pain and other indicatons |
-
2011
- 2011-04-04 US US13/635,303 patent/US9193697B2/en active Active
- 2011-04-04 CN CN2011800173842A patent/CN102917704A/zh active Pending
- 2011-04-04 JP JP2013503806A patent/JP2013523814A/ja active Pending
- 2011-04-04 CA CA2793900A patent/CA2793900A1/en not_active Abandoned
- 2011-04-04 EP EP11766539.8A patent/EP2555772B1/en active Active
- 2011-04-04 WO PCT/US2011/031040 patent/WO2011126960A1/en not_active Ceased
- 2011-04-04 BR BR112012023974A patent/BR112012023974A2/pt not_active IP Right Cessation
- 2011-04-04 AU AU2011238487A patent/AU2011238487B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013523814A (ja) | 2013-06-17 |
| WO2011126960A1 (en) | 2011-10-13 |
| EP2555772A1 (en) | 2013-02-13 |
| US9193697B2 (en) | 2015-11-24 |
| US20130018048A1 (en) | 2013-01-17 |
| EP2555772B1 (en) | 2017-01-11 |
| AU2011238487B2 (en) | 2015-10-01 |
| AU2011238487A1 (en) | 2012-09-13 |
| CA2793900A1 (en) | 2011-10-13 |
| EP2555772A4 (en) | 2013-08-28 |
| CN102917704A (zh) | 2013-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012023974A2 (pt) | composto, composição farmacêutica, método de tratar uma doença mediada com faah, e, uso de um composto. | |
| BR112012023971A2 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
| BR112012028055A2 (pt) | composto, uso do mesmo, composição farmacêutica, e, métodos de tratar uma doença mediada | |
| BR112012018913A2 (pt) | "composição farmacêutica, e, uso da composição" | |
| BR112012003464B8 (pt) | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica | |
| BR112012014180A2 (pt) | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| EA201390409A1 (ru) | Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием | |
| EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
| TW200740801A (en) | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| NZ610689A (en) | Substituted 6-amino-nicotinamides as kcnq2/3 modulators | |
| EA200970931A1 (ru) | Аналоги гетероариламидов | |
| EA201171285A1 (ru) | Новая технология изготовления диклофенака | |
| BR112015008297A2 (pt) | antagonistas de mglu2/3 para o tratamento de distúrbios autistas | |
| ATE555116T1 (de) | Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie | |
| EA201171283A1 (ru) | Новая технология изготовления мелоксикама | |
| EA201300988A1 (ru) | Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол | |
| UA99582C2 (ru) | Ветеринарная фармацевтическая композиция и способ (варианты) профилактики и лечения заболеваний жкт и интоксикаций разной этиологии у животных | |
| Malewicz et al. | Topical capsaicin in poly (lactic-co-glycolic) acid (PLGA) nanoparticles decreases acute itch and heat pain | |
| BR112012017994A2 (pt) | composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| Mantuano et al. | β-Dystroglycan restoration and pathology progression in the dystrophic mdx mouse: outcome and implication of a clinically oriented study with a novel oral dasatinib formulation | |
| UA112418C2 (uk) | Терапевтичний болезаспокійливий засіб | |
| PA8769601A1 (es) | Moduladores tetrahidro-pyrazolo-piridina unidos a carbono de catepsina s |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |